Are GLP-1 receptor agonists (GLP-1 RAs) destined to become lifelong medications? This question has sparked intense debate, especially after a recent systematic review published in the BMJ (https://www.bmj.com/content/392/bmj-2025-085304) shed light on what happens when patients stop these treatments. But here’s where it gets controversial: while these drugs are effective, their benefits often vanish once discontinued, leaving many to wonder if they’re a sustainable solution or just a temporary fix. And this is the part most people miss—it’s not just about weight regain; it’s about the broader implications for long-term health and treatment strategies.
The study revealed that weight regain after stopping GLP-1 RAs can be alarmingly rapid, sometimes faster than with other weight-loss methods. But weight isn’t the only concern. Cardiometabolic markers like blood pressure, glucose, and lipid levels also tend to revert to pre-treatment levels. As prescriptions for these drugs soar, a critical question emerges: should patients even start them in the first place? To dig deeper, we spoke with experts to unpack the evidence.
Weight regain is predictable, but it’s not the real issue. Professor Clare Collins, a nutrition and dietetics expert at the University of Newcastle, wasn’t surprised by the rapid weight regain. ‘This is exactly what you’d expect,’ she explained. For her, the findings underscore a fundamental principle of chronic disease management: when treatment stops, the condition often returns. ‘If someone stops antihypertensives, their blood pressure rises—it’s the same concept,’ she added. While predictable, this rebound highlights the need for better long-term maintenance strategies.
What’s more concerning, according to Prof Collins, is the deterioration in metabolic markers once treatment stops. ‘This is why we need to rethink long-term maintenance,’ she emphasized. Boldly put, this isn’t a sign of treatment failure—it’s a reflection of how these drugs work. Associate Professor Trevor Steward, from the Melbourne School of Psychological Sciences, agrees. GLP-1 RAs don’t create permanent changes; they amplify existing hormonal signals related to appetite, digestion, and satiety. When the drugs stop, so do their effects.
However, the mechanisms behind this rapid rebound aren’t fully understood. ‘Some evidence suggests these newer medications may cause a stronger “slingshot effect,”’ A/Prof Steward noted. Prof Collins added that incretin therapies may cross the blood-brain barrier, influencing reward pathways tied to appetite and food cues. For instance, ‘food noise’—like impulsively buying donuts with your bread—may decrease during treatment but return once it stops. This is where tapering, behavioral support, and nutrition strategies become crucial.
And this is the part most people miss: nutrition is often the missing variable in incretin trials. Prof Collins’s recent systematic review (https://pubmed.ncbi.nlm.nih.gov/41491340/) found that only two out of many phase three trials measured dietary intake. Most provided generic advice without tracking what patients actually ate. ‘Reducing intake doesn’t guarantee better nutrition,’ she warned. Micronutrient deficiencies and muscle loss can occur if diet quality isn’t monitored.
Pharmacists, with their frequent patient interactions, are uniquely positioned to spot emerging issues and refer patients to dietitians for medical nutrition therapy. The University of Newcastle offers resources like a healthy eating quiz and obesity management podcast (https://nomoneynotime.com.au/) to support this. When rapid weight loss or deterioration occurs, referral to a GP or dietitian becomes essential.
But here’s where it gets controversial: are GLP-1 RAs becoming lifelong treatments? A/Prof Steward argues that for patients with repeated cycles of weight loss and regain, these drugs may be a lower-risk option compared to long-term obesity. ‘Clinicians are increasingly viewing them as lifelong treatments, similar to medications for other chronic conditions,’ he said. However, he admits, ‘We’re still operating in the dark when it comes to tapering and maintenance.’
This raises a thought-provoking question: should patients commit to potentially lifelong treatment, or is there a middle ground? Prof Collins suggests that while the BMJ findings shouldn’t deter prescribing, cost and expectations must be discussed upfront. ‘These medications are a long-term investment, like a car or phone,’ she said. ‘We don’t yet know if patients can take breaks and reinitiate treatment later.’
As use grows, clear clinical messaging is critical. With over half a million Australians on these drugs, clinicians need more evidence on tapering and maintenance. What do you think? Are GLP-1 RAs a sustainable solution, or are we setting patients up for a lifelong dependency? Share your thoughts in the comments. For more insights, read the AP CPD article on weight loss management (https://www.australianpharmacist.com.au/weight-loss-management-cpd/).
